Christopher Yea - Net Worth and Insider Trading

Christopher Yea Net Worth

The estimated net worth of Christopher Yea is at least $6 Million dollars as of 2026-08-11. Christopher Yea is the CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals Inc and owns about 229,918 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $6 Million. Details can be seen in Christopher Yea's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Yea has not made any transactions after 2026-05-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Christopher Yea

To

Are these stocks worth buying? — GuruFocus analysis for each holding

Christopher Yea Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Yea owns 1 companies in total, including KalVista Pharmaceuticals Inc (KALV) .

Click here to see the complete history of Christopher Yea’s form 4 insider trades.

Insider Ownership Summary of Christopher Yea

Ticker Company Transaction Date Type of Owner
KALV KalVista Pharmaceuticals Inc 2026-05-27 Chief Development Officer

Christopher Yea Latest Holdings Summary

Christopher Yea currently owns a total of 1 stock. Christopher Yea owns 229,918 shares of KalVista Pharmaceuticals Inc (KALV) as of May 27, 2026, with a value of $6 Million.

Latest Holdings of Christopher Yea

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KALV KalVista Pharmaceuticals Inc 2026-05-27 229,918 27.00 6,207,786

Holding Weightings of Christopher Yea


Christopher Yea Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher Yea has made a total of 31 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 0 buys and 31 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 33,800 shares on May 27, 2026, which brought Christopher Yea around $905,164.

Insider Trading History of Christopher Yea

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher Yea Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks
See GF Score, valuation, financials, and warning signs for every stock Christopher Yea owns.
View KALV Analysis

Christopher Yea Ownership Network

Ownership Network List of Christopher Yea

No Data

Ownership Network Relation of Christopher Yea

Insider Network Chart


Christopher Yea Owned Company Details

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Christopher Yea is the Chief Development Officer of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Medical Officer Paul K. Audhya , Chief Commercial Officer Nicole Sweeny , and CFO and Secretary Benjamin L Palleiko .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Christopher Yea made 17 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net sale of 100,279. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 159,407 shares made by Benjamin L Palleiko , a net sale of 44,877 shares made by Paul K. Audhya , and a net sale of 16,344 shares made by Nicole Sweeny .

In summary, during the past 3 months, insiders sold 65,404 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 65,404 shares. During the past 18 months, 545,127 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 186,700 shares were bought by its insiders, resulting in a net sale of 358,427 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Christopher Yea Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Yea. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Christopher Yea's mailing address is: Cambridge Ma 02142.